---
title: 'Bio-Analytical Co-op-Northeastern Students at Seaport Therapeutics'
canonical: 'https://feeny.ai/job/bio-analytical-co-op-northeastern-students-seaport-therapeutics-boston-v2126dtdw6s0'
type: 'job'
last_seen: '2026-09-06'
---

# Bio-Analytical Co-op-Northeastern Students at Seaport Therapeutics

- **Company:** Seaport Therapeutics
- **Location:** Boston, MA
- **Posted:** 2026-08-20
- **Last confirmed live:** 2026-09-06
- **Apply:** https://job-boards.greenhouse.io/seaporttherapeutics/jobs/5396977008

## Job description

Seaport Therapeutics is a clinical-stage therapeutics company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary GlyphTM technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and are guided by an extensive network of renowned scientists, clinicians and key opinion leaders. For more information, please visit [www.seaporttx.com](https://www.seaporttx.com/).

Job Description

Seaport Therapeutics is seeking a co-op student for a lab-based bioanalysis position to be part of our Discovery team. This co-op will have a focus on LC-MS to assist in the screening of novel drugs. We are looking for a highly motivated individual who is looking to be a part of a multidisciplinary team and to gain experience in a startup environment. This position will contribute to advancing the pipeline of impactful candidates generated from our novel Glyph™ prodrug platform.

Some of the responsibilities will include:

- Executing in vitro experiments, using LC-MS, for the screening of lipid prodrugs to support preclinical discovery
- Processing and analyzing in vivo samples (plasma, lymph fluid, etc.) to generate DMPK data for various prodrugs
- Contributing to the development and optimization of LC-MS methods for both quantitative and qualitative analysis
- Routine use and troubleshooting of LC-MS instrumentation
- Documenting all experiments using an electronic notebook and analyzing data for reports and regular internal presentations

## Experience and Skills

- Enrolled in a Chemistry, Biochemistry, Pharmaceutical Sciences, Chemical Engineering, or related program at the Master’s Level
- Previous Co-op or lab experience is preferred
- Knowledge of or experience with: HPLC, reverse phase chromatography, mass spectrometry instrumentation, enzyme kinetics, protein precipitation, liquid-liquid extraction
- Strong organizational skills, attention to detail, and eagerness to learn.

## About Seaport Therapeutics

## Company Overview
- **One-liner**: Seaport Therapeutics is a clinical-stage biotech company developing novel oral prodrugs for depression and anxiety using its proprietary Glyph™ platform to overcome bioavailability and side effect limitations.
- **Entity Type**: Private (clinical-stage; raised $340M in funding across Series A, Series B, and a government grant)
- **Headquarters**: Boston, Massachusetts, United States
- **Founded**: Not publicly available (the company launched as a PureTech Health-founded entity around 2023–2024, based on Series A timing)
- **Founders**: Daphne Zohar (CEO), Michael C. Chen (Co-founder, Chief Scientific Officer); the Glyph platform was co-invented by Jamie Simpson and Dan Bonner of Monash University, who are now part of the team.

## Core Business
- **Primary industry**: Biotechnology / Neuropsychiatric Drug Development
- **Target customers**: Patients with major depressive disorder, generalized anxiety disorder, and other neuropsychiatric conditions; partners and prescribers in psychiatry/neurology
- **Mission or purpose statement**: “Unlocking Better Days™” – developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders.

## Products & Services
- **Glyph™ Platform**: A proprietary oral prodrug technology that enables more medicine to reach the bloodstream and brain while avoiding first-pass liver metabolism and reducing side effects like hepatotoxicity. The platform is licensed exclusively from Monash University.
- **GlyphAgo™ (SPT-320)**: Oral prodrug of agomelatine for Generalized Anxiety Disorder (GAD); Phase 1 proof-of-concept data reported in June 2026 show positive multiple-ascending dose results.
- **GlyphAllo™ (SPT-300)**: Oral prodrug of allopregnanolone for Major Depressive Disorder (MDD); designed to overcome low oral bioavailability and avoid side effects like sexual dysfunction and weight gain.
- **Glyph2BLSD™ (SPT-348)**: Oral prodrug of 2-bromo-LSD, a non-hallucinogenic neuroplastogen for multiple indications including treatment-resistant depression, PTSD, and headache disorders; preclinical stage.

## Market Standing
- **Valuation/Market Cap**: Not disclosed
- **Key Metric**: **Total Funding** – $340M as of March 2026
- **Notable Investors/Partners**:
  - Series A (April 2024): $100M led by Sofinnova Investments and ARCH Venture Partners
  - Series B (October 2024): $225M led by General Atlantic
  - Grant (March 2026): $15M from ARPA-H
  - Corporate round (January 2024): undisclosed investor
  - Strategic collaboration with Monash University (exclusive license for Glyph platform)
- **Growth Signals**:
  - Headcount grew **46.8% YoY** (from ~30 to 52 employees)
  - Positive Phase 1 proof-of-concept data for GlyphAgo (June 2026)
  - Active job postings (5 open roles as of mid-2026)
  - Strong talent inflow from PureTech Health, Karuna Therapeutics, and Bristol Myers Squibb

## Competitive Advantages
- **Proprietary Glyph™ platform** that clinically validates mechanisms previously limited by poor oral bioavailability or liver toxicity (e.g., allopregnanolone, agomelatine, 2-bromo-LSD)
- **Experienced leadership** with deep history in neuropsychiatric drug development (PureTech Health founders, Karuna veterans)
- **First/best-in-class potential** for each pipeline candidate, enabling a pipeline of multiple assets from a single validated platform
- **Worldwide exclusive license** to Monash University’s intellectual property, creating a strong IP moat

## Strategic Focus
- Advance GlyphAgo into Phase 2 trials for GAD
- Progress GlyphAllo and Glyph2BLSD through Phase 1 and toward proof-of-concept
- Expand the pipeline into additional neuropsychiatric indications (TRD, PTSD, headache disorders)
- Continue hiring across clinical development, CMC, biometrics, and program leadership roles

## Why Work Here
- **Mission-driven culture**: Focus on “Unlocking Better Days” for patients with serious mental health conditions
- **Location**: Boston Seaport district (101 Seaport, Boston, MA) – a hub for biotech innovation
- **Growth trajectory**: ~50% headcount growth in the past year signals a rapidly scaling organization with advancement opportunities
- **Team composition**: Small but experienced team (52 employees) with a high ratio of directors/managers (29% director-level), offering exposure to senior leadership
- **Flexibility**: Hybrid/office policy not explicitly stated, but the company has a physical office and lists in-person roles; likely offers flexibility typical of Boston biotechs
- **Culture highlights**: Featured office tour with CEO Daphne Zohar, an emphasis on collaboration and scientific excellence, and strong ties to PureTech Health’s entrepreneurial ecosystem

## Sources
1. [seaporttx.com](https://seaporttx.com/)
2. [seaporttx.com/our-pipeline/](https://seaporttx.com/our-pipeline/)
3. [seaporttx.com/careers/](https://seaporttx.com/careers/)
4. [LinkedIn – Seaport Therapeutics](https://www.linkedin.com/company/seaport-therapeutics)
5. [job-boards.greenhouse.io/seaporttherapeutics](http://job-boards.greenhouse.io/seaporttherapeutics)

## Other roles at Seaport Therapeutics

- [Associate Director, Program Manager](https://feeny.ai/job/associate-director-program-manager-seaport-therapeutics-boston-dsw8wae6kyqh) — Boston, MA
- [Associate Director, Quality Assurance - CMC](https://feeny.ai/job/associate-director-quality-assurance-cmc-seaport-therapeutics-boston-11nqc9m63rgr) — Boston, MA
- [Clinical Trial Manager](https://feeny.ai/job/clinical-trial-manager-seaport-therapeutics-boston-7mer32eraw71) — Boston, MA
- [Director, Clinical Quality Assurance](https://feeny.ai/job/director-clinical-quality-assurance-seaport-therapeutics-boston-e2kywkseea5x) — Boston, MA
- [Senior Director, Analytical Research & Development](https://feeny.ai/job/senior-director-analytical-research-development-seaport-therapeutics-boston-t9e9pmwrsw0g) — Boston, MA
- [Executive Director/Vice President, Clinical Development](https://feeny.ai/job/executive-director-vice-president-clinical-development-seaport-therapeutics-te8jxxh62he1) — Boston, MA